Drug Trial Radar · NCT04991116
Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis
Last checked: Nov 19, 2026Latest source record: Mar 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
529
Actual
Start
Jun 30, 2022
Primary completion
Dec 2028
Study completion Apr 2029
Sponsor
- Lead sponsor
- Sun Pharmaceutical Industries LimitedIndustry
- Sponsor type
- Industry
- First posted
- Aug 5, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
An open label phase 3 study
Conditions
- Psoriatic Arthritis
Interventions
TILD sub-cutaneous (SC) injectionDrug
1 mL injection of study medication
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and intensity of Adverse Events (AEs) recorded through the study periodTime frame: Week 124
- Proportion of Subject Who Reached (American College of Rheumatology Score of 20) ACR20Time frame: Week 124
- Proportion of Subjects Who Reached (American College of Rheumatology Score of 50) ACR50Time frame: Week 124
- Proportion of Subjects Who Reached (American College of Rheumatology Score of 70) ACR70Time frame: Week 124
Locations
99 sites in 14 countries. Site status is shown where the registry gives one.
Sunpharma site no 50
Dothan, Alabama
Sunpharma site no 80
Gilbert, Arizona
Sunpharma site no 65
Mesa, Arizona
Sunpharma site no 105
Phoenix, Arizona
Sunpharma site no. 30
Covina, California
Sunpharma site no 110
Encino, California
Sunpharma site no. 17
Fountain Valley, California
Sunpharma site no. 15
Thousand Oaks, California
Sunpharma site no 113
Avon Park, Florida
Sunpharma site no. 21
Clearwater, Florida
Sunpharma site no. 02
Hialeah, Florida
Sunpharma site no 71
Kissimmee, Florida
Sunpharma site no 107
Margate, Florida
Sunpharma site no. 05
New Port Richey, Florida
Sunpharma site no 32
Ocoee, Florida
SunPharma Site no 22
Tamarac, Florida
Sunpharma site no 52
Gainesville, Georgia
Sunpharma site no 51
Orland Park, Illinois
Sunpharma site no 49
Schaumburg, Illinois
Sunpharma site no 47
Skokie, Illinois
Sunpharma site no. 20
Wichita, Kansas
Sunpharma site no. 14
Springfield, Missouri
Sunpharma site no 104
St Louis, Missouri
Sunpharma site no 48
Kalispell, Montana
Sunpharma Site no 27
Lincoln, Nebraska
Sunpharma site no 33
Voorhees Township, New Jersey
Sunpharma site no 34
Charlotte, North Carolina
Sunpharma site no 111
Leland, North Carolina
Sunpharma site no 53
Wilmington, North Carolina
Sunpharma site no 35
Minot, North Dakota
Sunpharma site no. 11
Middleburg Heights, Ohio
Sunpharma site no 31
Greenville, South Carolina
Sunpharma site no. 08
Baytown, Texas
Sunpharma site no. 13
Baytown, Texas
Sunpharma Site no 28
Lubbock, Texas
Sunpharma site no 109
Mesquite, Texas
Sunpharma site no. 03
San Antonio, Texas
Sunpharma site no. 16
San Antonio, Texas
Sunpharma site no. 01
Tomball, Texas
Sunpharma site no 96
Salt Lake City, Utah
Showing 40 of 99 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.